Frazier Life Sciences Takes 10.4% Stake in MBX Biosciences
Ticker: MBX · Form: SC 13D · Filed: Sep 23, 2024 · CIK: 1776111
Sentiment: neutral
Topics: activist-filing, life-sciences, pharmaceuticals, ownership-stake
TL;DR
**Frazier Life Sciences now owns 10.4% of MBX Biosciences (1.7M shares).**
AI Summary
On September 23, 2024, Frazier Life Sciences Public Fund, L.P. and its affiliates, including Albert Cha and Daniel Estes, reported a beneficial ownership of 1,700,000 shares of MBX Biosciences, Inc., representing 10.4% of the outstanding shares. This filing indicates a significant stake by Frazier Life Sciences in MBX Biosciences, Inc.
Why It Matters
This filing signals a substantial investment by a known life sciences fund, potentially indicating confidence in MBX Biosciences' future prospects or a strategic interest in the company.
Risk Assessment
Risk Level: medium — The filing indicates a significant ownership stake, which could lead to increased influence or potential future actions by the reporting group, but does not specify any immediate threats or changes.
Key Numbers
- 1,700,000 — Shares Owned (Represents the total number of MBX Biosciences, Inc. shares beneficially owned by the reporting group.)
- 10.4% — Ownership Percentage (Indicates the significant stake Frazier Life Sciences holds in MBX Biosciences, Inc.)
Key Players & Entities
- Frazier Life Sciences Public Fund, L.P. (company) — Reporting entity
- MBX Biosciences, Inc. (company) — Subject company
- Albert Cha (person) — Group member
- Daniel Estes (person) — Group member
- 1,700,000 (dollar_amount) — Number of shares owned
- 10.4% (dollar_amount) — Percentage of shares owned
FAQ
Who are the primary filers of this SC 13D?
The primary filers are Frazier Life Sciences Public Fund, L.P. and its affiliated entities, including FHMLS X, L.L.C., FHMLS X, L.P., FHMLS XI, L.L.C., FHMLS XI, L.P., FHMLSP OVERAGE, L.L.C., FHMLSP OVERAGE, L.P., FHMLSP, L.L.C., FHMLSP, L.P., FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P., FRAZIER LIFE SCIENCES X, L.P., FRAZIER LIFE SCIENCES XI, L.P., along with individuals Albert Cha, Daniel Estes, James Brush, James N. Topper, and Patrick J. Heron.
What is the subject company?
The subject company is MBX Biosciences, Inc., with Central Index Key 0001776111 and Standard Industrial Classification code 2834 (Pharmaceutical Preparations).
What is the total number of shares owned by the reporting group?
The reporting group beneficially owns 1,700,000 shares of MBX Biosciences, Inc.
What percentage of MBX Biosciences, Inc. does the reporting group own?
The reporting group owns 10.4% of the outstanding shares of MBX Biosciences, Inc.
When was this filing submitted?
This SC 13D filing was submitted on September 23, 2024.
Filing Stats: 4,778 words · 19 min read · ~16 pages · Grade level 4.6 · Accepted 2024-09-23 10:48:27
Filing Documents
- d810878dsc13d.htm (SC 13D) — 377KB
- d810878dex99a.htm (EX-99.A) — 28KB
- 0001193125-24-223402.txt ( ) — 407KB
From the Filing
SC 13D 1 d810878dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON , D.C. 20549 SCHEDULE 13D U NDER THE S ECURITIES E XCHANGE A CT OF 1934 (Amendment No. )* MBX Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55287L101 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 16, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 55287L101 1. Name of Reporting Persons. Frazier Life Sciences Public Fund, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 1,103,920 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 1,103,920 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,103,920 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 3.5% (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of 1,103,920 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. (2) Based on 31,853,698 shares of Common Stock that were anticipated to be outstanding following the Issuers initial public offering as set forth in the Issuers final prospectus filed with the SEC pursuant to Rule 424(b)(5) on September 13, 2024. Page 2 CUSIP No. 55287L101 1. Name of Reporting Persons. FHMLSP, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 1,103,920 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 1,103,920 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,103,920 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 3.5% (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of 1,103,920 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. (2) Based on 31,853,698 shares of Common Stock that were anticipated to be outstanding following the Issuers initial public offering as set forth in the Issuers final prospectus filed with the SEC pursuant to Rule 424(b)(5) on September 13, 2024. Page 3 CUSIP No. 55287L101 1. Name of Reporting Persons. FHMLSP,